Skip to main content
SCI logo

SCI — Investor Relations & Filings

Ticker · 4119 ISIN · TW0004119003 TW Manufacturing
Open in API
Filings indexed 1,697 across all filing types
Latest filing 2020-12-02 Regulatory Filings
Country TW Taiwan
Listing TW 4119

About SCI

www.sci-pharmtech.com.tw

SCI Pharmtech, Inc. specializes in the research, development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. Established in 1987 and originally founded by the Swiss Siegfried Group, the company provides high-quality chemical solutions and custom manufacturing services to leading global pharmaceutical corporations across Europe, North America, and Japan. Its core operations encompass advanced chemical synthesis, process optimization, and large-scale production within GMP-compliant facilities. With a robust R&D infrastructure including specialized laboratories and pilot plants, the company delivers technical excellence in complex chemical processing. SCI Pharmtech maintains a strong focus on quality assurance and international regulatory compliance, positioning itself as a reliable partner for the global healthcare and life sciences sectors.

Recent filings

Filing Released Lang Actions
109年第3季財務報告書 — 202001_4119_AI1.pdf
Regulatory Filings
2020-12-02 Chinese
109年10月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders and related parties of the company 旭富製藥科技股份有限公司, including directors, managers, and major shareholders. It lists the number of shares held, pledged shares, and related ratios. The document is focused on insider shareholdings and does not contain financial statements, earnings data, or management discussion. It is not a report or announcement of financial results, nor a regulatory filing about management changes or voting results. The content matches the definition of a Director's Dealing report, which involves reporting personal share transactions or holdings by company directors and executives. The document length is 3152 characters, which is consistent with a detailed insider shareholding report rather than a brief announcement or a full financial report. Therefore, the most appropriate classification is Director's Dealing (DIRS).
2020-11-11 Chinese
109年10月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document is a detailed tabular disclosure of shareholdings by insiders, including directors, managers, and their related parties. It lists share counts, changes in holdings, and related notes. There is no indication of financial statements, earnings data, or management discussion. The content focuses on insider share transactions and holdings. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is sufficient and contains substantive data on insider holdings, not just an announcement or summary. Therefore, the appropriate classification is DIRS.
2020-11-11 Chinese
109年10月營業收入
Interim / Quarterly Report Classification · 85% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 旭富, presented in a tabular format with explanations about accounting standards and reporting practices. It contains specific financial data for a particular month and year (October 2020, 民國109年10月) and compares it to the previous year. The document is short (773 characters) and appears to be a periodic financial summary rather than a full comprehensive report. It does not contain detailed financial statements or extensive analysis typical of an Interim/Quarterly Report (IR) but provides substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits best as an Interim / Quarterly Report (IR).
2020-11-09 Chinese
109年10月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a listed company (旭富) providing information about fund loans and endorsement guarantees for the current and previous months, including cumulative amounts and limits. The content is brief, factual, and does not contain detailed financial statements or analysis. It is a regulatory disclosure related to financial guarantees and loans, typical of a general regulatory announcement rather than a full financial report or audit. The document length is short (601 characters), and it does not present comprehensive financial data or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2020-11-09 Chinese
本公司董事會通過對關係人捐贈事宜
Regulatory Filings Classification · 95% confidence The document is a short announcement (660 characters) from a company (4119 旭富) regarding a board resolution approving a related party donation. It includes details such as the donation amount, recipient, and board approval dates. There is no financial statement, no detailed report, no earnings data, and no mention of a report being attached or published. The content is about a board decision on a specific transaction, not a full management or financial report. This fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2020-11-06 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.